{"id":3790,"count":5,"description":"Hypothyreose \u2014 en underaktiv skjoldbruskkjertel \u2014 rammer omtrent <strong>5% av voksne worldwide<\/strong>, med kvinner som diagnostiseres fem til ti ganger hyppigere enn menn. Skjoldbruskkjerten sitter foran p\u00e5 halsen og produserer to hormoner: <strong>tyroksin (T4)<\/strong> og <strong>triiodotyronin (T3)<\/strong>, som sammen setter metabolsk hastighet for hver enkelt celle i kroppen. N\u00e5r kjerten svikter \u2013 vanligvis p\u00e5 grunn av autoimmun \u00f8deleggelse (Hashimotos thyreoiditt), kirurgi for knuter eller kreft, radiojodbehandling, medf\u00f8dt frav\u00e6r eller alvorlig jodmangel \u2013 oppst\u00e5r symptomene gradvis: tretthet, vekt\u00f8kning, kuldeintoleranse, forstoppelse, t\u00f8rr hud, h\u00e5ravfall, depresjon og hjerne-t\u00e5ke. Ubehandlet hypotyreose under graviditet \u00f8ker risikoen for spontanabort og hemmer fosterets nevrologiske utvikling. Diagnosen er biokjemisk: forh\u00f8yet <strong>tyreoideastimulerende hormon (TSH)<\/strong> med lavt eller lavt-normalt <strong>fritt T4<\/strong>.\n\nTreatment is hormone replacement. The first-line drug is <strong>levotyroksin<\/strong> &mdash; synthetic T4 &mdash; taken once daily on an empty stomach. Levothyroxine has a long half-life (~7 days) which produces smooth blood levels with simple once-daily dosing. The body converts T4 to the more active T3 in peripheral tissues exactly as it does with the natural hormone, which is why most patients feel completely well on T4 alone. Dose is titrated against TSH every 6&ndash;8 weeks until the level sits in the target range (usually 0.5&ndash;2.5 mIU\/L), then monitored annually.\n\nLevothyroxine (T4) brands stocked at MedsBase\nAll four brands below contain the identical active ingredient &mdash; <strong>levotyroksin natrium<\/strong>. De skiller seg i produsent, hjelpestoffer og prisniv\u00e5. N\u00e5r TSH-en din er stabil p\u00e5 ett merke, er det \u00e5 holde seg til det for \u00e5 unng\u00e5 de sm\u00e5 bioekvivalensvariasjonene som kan f\u00f8re til at TSH g\u00e5r utenfor m\u00e5lomr\u00e5det.\n\n<a href=\"https:\/\/medsbase.com\/nb\/eltroxin\/\"><strong>Eltroxin<\/strong><\/a> \u2014 GlaxoSmithKline (GSK), 100 mcg tablett. Globalt anerkjent merke brukt siden 1960-tallet; samme molekyl som Synthroid og Levoxyl.\n<a href=\"https:\/\/medsbase.com\/nb\/thyronorm\/\"><strong>Thyronorm<\/strong><\/a> \u2014 Abbott India, full 25\/50\/100\/125\/150 mcg titreringsomr\u00e5de. Den mest utbredt foreskrevne levotyroxin i India.\n<a href=\"https:\/\/medsbase.com\/nb\/thyrox\/\"><strong>Thyrox<\/strong><\/a> \u2014 Macleods Pharmaceuticals, 25\/100\/125\/200 mcg. Inkluderer den h\u00f8yere 200 mcg styrken som er nyttig for TSH-undertrykkelse etter thyreoidektomi.\n<a href=\"https:\/\/medsbase.com\/nb\/l-thyroid\/\"><strong>L-Thyroid<\/strong><\/a> &mdash; budget option, full 25 to 150 mcg titration range.\n\n\nLiothyronine (T3) &mdash; second-line\n<a href=\"https:\/\/medsbase.com\/nb\/liothyronine\/\"><strong>Liothyronin 25 mcg<\/strong><\/a> is synthetic T3 &mdash; about four times more potent than levothyroxine, with a much shorter half-life (~24 hours). Liothyronine bypasses the T4-to-T3 conversion step entirely. Its place in therapy is narrow:\n\nA <strong>liten tilleggsdose sammen med levotyroxin<\/strong> in selected patients with persistent hypothyroid symptoms despite a normal TSH on T4 monotherapy &mdash; usually a specialist endocrinology decision after other causes are excluded.\nShort-term <strong>forberedelse til skjoldbruskkjertelkreft-skanninger<\/strong> (tillater raskere TSH-\u00f8kning etter opph\u00f8r).\n<strong>Myks\u00f8demkoma<\/strong> in hospital, given intravenously alongside T4.\nOff-label augmentation in <strong>forsterkning ved behandlingsresistent depresjon<\/strong>.\n\nLiothyronine is <strong>ikke<\/strong> a wholesale replacement for levothyroxine and is not a weight-loss drug &mdash; misuse in euthyroid people causes atrial fibrillation, bone loss and muscle wasting. The Cochrane systematic review found no consistent benefit of T4+T3 over T4 monotherapy for routine quality-of-life improvement.\n\nThyroid nutritional support &mdash; not a treatment substitute\n<a href=\"https:\/\/medsbase.com\/nb\/thyropace\/\"><strong>Thyropace<\/strong><\/a> er et L-Tyrosin + Jod kapseltilskudd. Det er inkludert i denne kategorien fordi det st\u00f8tter skjoldbruskkjertelens funksjon ern\u00e6ringsmessig, men det er ikke <strong>ikke<\/strong> a substitute for levothyroxine in diagnosed hypothyroidism. Thyropace can be appropriate for confirmed mild iodine deficiency or as adjunct nutritional support during pregnancy. It should be avoided in autoimmune Hashimoto&rsquo;s thyroiditis, Graves&rsquo; disease, and before radioiodine scanning &mdash; excess iodine flares autoimmunity and complicates radio-tracer imaging.\n\nCritical absorption rules for any T4 or T3 product\nLevothyroxine and liothyronine absorption are dramatically reduced by food, coffee, soy and several common medications. The rules below are essential, not optional:\n\nTake on an <strong>tom mage<\/strong>, first thing in the morning, with plain water.\nWait <strong>30\u201360 minutter<\/strong> before any food, coffee or other tablet.\nSeparate from <strong>kalsium, jern, magnesium, sink, aluminium<\/strong> supplements \/ antacids by at least 4 hours.\nSeparate from <strong>protonpumpehemmere<\/strong> (omeprazole, esomeprazole, pantoprazole) &mdash; gastric acid is needed for full absorption.\nSeparate from <strong>kolestyramin, sevelamer, orlistat<\/strong> med minst 4 timers mellomrom.\n<strong>Graviditet:<\/strong> behovet for levotyroksin \u00f8ker 25\u201350% midt i svangerskapet \u2014 kontroller TSH hver 4. uke i f\u00f8rste halvdel av svangerskapet.\n<strong>Eldre\/hjertesyke pasienter:<\/strong> start low (25&ndash;50 mcg) and titrate slowly to avoid triggering ischaemia or atrial fibrillation.\n\n\nEvery product in this category is dispatched from a <strong>WHO-GMP-sertifisert produsent<\/strong>, FDA-godkjent generisk der aktuelt, med diskret emballasje og verdensomspennende frakt. Hver produktside inkluderer en TSH-titreringsoversikt, fullstendig liste over legemiddelinteraksjoner, bivirkningsprofil ved over- vs underbehandling, og et h\u00e5ndplukket panel med alternativer.","link":"https:\/\/medsbase.com\/nb\/underactive-thyroid-treatment\/","name":"Behandling av underaktiv skjoldbruskkjertel","slug":"underactive-thyroid-treatment","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat\/3790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product?product_cat=3790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}